UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 1.109

Sortiert nach

Enhancing the effect of THERATOPE STn-KLH cancer vaccine in patients with metastatic breast cancer by pretreatment with low-dose intravenous cyclophosphamide

Journal of immunotherapy with emphasis on tumor immunology, 1996-07, Vol.19 (4), p.309

1996

Volltextzugriff (PDF)

Clinical outcome of breast and ovarian cancer patients treated with high-dose chemotherapy, autologous stem cell rescue and THERATOPE® STn-KLH cancer vaccine

Bone marrow transplantation (Basingstoke), 2000-06, Vol.25 (12), p.1233-1241

2000

Volltextzugriff (PDF)

Antibodies against mucin-associated sialyl-Tn epitopes correlate with survival of metastatic adenocarcinoma patients undergoing active specific immunotherapy with synthetic STn vaccine

Journal of immunotherapy with emphasis on tumor immunology, 1996-01, Vol.19 (1), p.59

1996

Volltextzugriff (PDF)

Clear air boundary layer spaced antenna wind measurement with the Multiple Antenna Profiler (MAPR)

Annales geophysicae (1988), 2001-08, Vol.19 (8), p.845-854

2001

Volltextzugriff (PDF)

Anti‐MUC1 class I restricted CTLs in metastatic breast cancer patients immunized with a synthetic MUC1 peptide

International journal of cancer, 1998-06, Vol.76 (6), p.817-823

1998

Volltextzugriff (PDF)

Evidence of a cellular immune response against sialyl-Tn in breast and ovarian cancer patients after high-dose chemotherapy, stem cell rescue, and immunization with Theratope STn-KLH cancer vaccine

Journal of immunotherapy, 1999-01, Vol.22 (1), p.54-66

1999

Volltextzugriff (PDF)

Active immunization of human ovarian cancer patients against a common carcinoma (Thomsen-Friedenreich) determinant using a synthetic carbohydrate antigen

Journal of immunotherapy, 1992-05, Vol.11 (4), p.292

1992

Volltextzugriff (PDF)

Immunization of breast cancer patients using a synthetic sialyl-Tn glycoconjugate plus Detox adjuvant

Cancer Immunology Immunotherapy, 1993-07, Vol.36 (4), p.215-222

1993

Volltextzugriff (PDF)

Pre-immunotherapy serum CA27.29 (MUC-1) mucin level and CD69+ lymphocytes correlate with effects of Theratope® sialyl-Tn-KLH cancer vaccine in active specific immunotherapy

Cancer Immunology, Immunotherapy, 1996-06, Vol.42 (5), p.303-309

1996

Volltextzugriff (PDF)

CD69+ and HLA‐DR+ activation antigens on peripheral blood lymphocyte populations in metastatic breast and ovarian cancer patients: Correlations with survival following active specific immunotherapy

International journal of cancer, 1995-05, Vol.61 (4), p.470-474

1995

Volltextzugriff (PDF)

Monoclonal Antibodies and Synthetic Tumor-Associated Glycoconjugates in the Study of the Expression of Thomsen-Friedenreich-Like and Tn-Like Antigens on Human Cancers

JNCI : Journal of the National Cancer Institute, 1987-03, Vol.78 (3), p.489-496

1987

Volltextzugriff (PDF)

Radioimmunoscintigraphy in patients with breast adenocarcinoma using technetium-99m labelled monoclonal antibody 170H.82: report of a phase II study

European Journal of Nuclear Medicine, 1997-04, Vol.24 (4), p.381-389

1997

Volltextzugriff (PDF)

Phase II study to evaluate the toxicity and efficacy of concurrent cisplatin and radiation therapy in the treatment of patients with locally advanced squamous cell carcinoma of the cervix

Gynecologic oncology, 1995-07, Vol.58 (1), p.34-41

1995

Volltextzugriff (PDF)

Specificity of the IgG response in mice and human breast cancer patients following immunization against synthetic sialyl-Tn, an epitope with possible functional significance in metastasis

Advances in experimental medicine and biology, 1994, Vol.353, p.105

1994

Volltextzugriff (PDF)

Analysis of human tumor associated Thomsen-Friedenreich antigen

Cancer research (Chicago, Ill.), 1990-08, Vol.50 (15), p.4801-4808

1990

Volltextzugriff (PDF)

Immune Responses of Mice and Human Breast Cancer Patients following Immunization with Synthetic Sialyl-Tn Conjugated to KLH Plus Detox Adjuvant

Annals of the New York Academy of Sciences, 1993-08, Vol.690 (1), p.276-291

1993

Volltextzugriff (PDF)

The Niwot Ridge Subalpine Forest US-NR1 AmeriFlux site – Part 1: Data acquisition and site record-keeping

Geoscientific instrumentation, methods and data systems, 2016-09, Vol.5 (2), p.451-471

2016

Volltextzugriff (PDF)

A phase I/II study combining radical radiotherapy with concurrent cisplatin in the treatment of advanced squamous cell carcinoma of the cervix

International journal of gynecological cancer, 1992-07, Vol.2 (4), p.215-219

1992

Volltextzugriff (PDF)

Prognostic significance of preimmunotherapy serum CA27.29 (MUC-1) mucin level after active specific immunotherapy of metastatic adenocarcinoma patients

Journal of immunotherapy (1997), 1997-01, Vol.20 (1), p.70

1997

Volltextzugriff (PDF)

Novel, dose intensive, single-agent cisplatin in the first-line management of advanced stage ovarian cancer

International journal of gynecological cancer, 1992-11, Vol.2 (6), p.301-306

1992

Volltextzugriff (PDF)

Effective drug-antibody targeting using a novel monoclonal antibody against the proliferative compartment of mammalian squamous carcinomas

Cancer Immunology Immunotherapy, 1990-03, Vol.32 (2), p.105-109

1990

Volltextzugriff (PDF)

MAb 170H.82: an evaluation of a novel panadenocarcinoma monoclonal antibody labelled with 99Tcm and with 111In

Nuclear medicine communications, 1992-01, Vol.13 (1), p.11-19

1992

Volltextzugriff (PDF)

Decreased levels of circulating lytic anti-T in the serum of patients with metastatic gastrointestinal cancer: a correlation with disease burden

Clinical and experimental immunology, 1982-01, Vol.47 (1), p.176-182

1982

Volltextzugriff (PDF)

The effects of circulating antigen on the pharmacokinetics and radioimmunoscintigraphic properties of 99m Tc labelled monoclonal antibodies in cancer patients

Journal of pharmacy & pharmaceutical sciences, 1998-09, Vol.1 (3), p.115-125

1998

Volltextzugriff (PDF)

Radioimmunoscintigraphy in patients with breast adenocarcinoma using technetium-99m labelled monoclonal antibody 170H.82: report of a phase II study

European journal of nuclear medicine and molecular imaging, 1997-04, Vol.24 (4), p.381-389

1997

Volltextzugriff (PDF)

1 – 25 von 1.109

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(953)
Mit Volltextzugriff
(888)

Publikationsform

2 weitere anzeigen...

Weniger anzeigen...

Sprache

Englisch
(1.105)
Japanisch
(126)
Französisch
(19)
Norwegisch
(1)

Erscheinungsjahr

n.n

Thema

Science & Technology
(703)
Life Sciences & Biomedicine
(599)
Humans
(459)
Female
(279)
Male
(262)
Biological And Medical Sciences
(245)
Medical Sciences
(185)
Adult
(172)
Animals
(151)
Middle Aged
(147)
Aged
(121)
Physical Sciences
(90)
General & Internal Medicine
(86)
Medicine, General & Internal
(79)
Surgery
(73)
Fundamental And Applied Biological Sciences. Psychology
(63)
Biochemistry & Molecular Biology
(61)
Adolescent
(60)
Oncology
(54)
Time Factors
(52)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

The Lancet
(46)
Ostrich
(18)
Canadian Journal Of Surgery
(15)
Scottish Geographical Magazine
(14)
Canadian Medical Association Journal
(12)
Blood
(11)
Canadian Journal Of Chemistry
(11)
Midwives Chronicle
(11)
Journal Of The American College Of Surgeons
(10)
Physical Review. C
(9)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(4)

Menü

Weitere Dienste

Einstellungen

Enhancing the effect of THERATOPE STn-KLH cancer vaccine in patients with metastatic breast cancer by pretreatment with low-dose intravenous cyclophosphamide

Clinical outcome of breast and ovarian cancer patients treated with high-dose chemotherapy, autologous stem cell rescue and THERATOPE® STn-KLH cancer vaccine

Antibodies against mucin-associated sialyl-Tn epitopes correlate with survival of metastatic adenocarcinoma patients undergoing active specific immunotherapy with synthetic STn vaccine

Clear air boundary layer spaced antenna wind measurement with the Multiple Antenna Profiler (MAPR)

Anti‐MUC1 class I restricted CTLs in metastatic breast cancer patients immunized with a synthetic MUC1 peptide

Evidence of a cellular immune response against sialyl-Tn in breast and ovarian cancer patients after high-dose chemotherapy, stem cell rescue, and immunization with Theratope STn-KLH cancer vaccine

Active immunization of human ovarian cancer patients against a common carcinoma (Thomsen-Friedenreich) determinant using a synthetic carbohydrate antigen

Immunization of breast cancer patients using a synthetic sialyl-Tn glycoconjugate plus Detox adjuvant

Pre-immunotherapy serum CA27.29 (MUC-1) mucin level and CD69+ lymphocytes correlate with effects of Theratope® sialyl-Tn-KLH cancer vaccine in active specific immunotherapy

CD69+ and HLA‐DR+ activation antigens on peripheral blood lymphocyte populations in metastatic breast and ovarian cancer patients: Correlations with survival following active specific immunotherapy

Monoclonal Antibodies and Synthetic Tumor-Associated Glycoconjugates in the Study of the Expression of Thomsen-Friedenreich-Like and Tn-Like Antigens on Human Cancers

Radioimmunoscintigraphy in patients with breast adenocarcinoma using technetium-99m labelled monoclonal antibody 170H.82: report of a phase II study

Phase II study to evaluate the toxicity and efficacy of concurrent cisplatin and radiation therapy in the treatment of patients with locally advanced squamous cell carcinoma of the cervix

Specificity of the IgG response in mice and human breast cancer patients following immunization against synthetic sialyl-Tn, an epitope with possible functional significance in metastasis

Analysis of human tumor associated Thomsen-Friedenreich antigen

Immune Responses of Mice and Human Breast Cancer Patients following Immunization with Synthetic Sialyl-Tn Conjugated to KLH Plus Detox Adjuvant

The Niwot Ridge Subalpine Forest US-NR1 AmeriFlux site – Part 1: Data acquisition and site record-keeping

A phase I/II study combining radical radiotherapy with concurrent cisplatin in the treatment of advanced squamous cell carcinoma of the cervix

Prognostic significance of preimmunotherapy serum CA27.29 (MUC-1) mucin level after active specific immunotherapy of metastatic adenocarcinoma patients

Novel, dose intensive, single-agent cisplatin in the first-line management of advanced stage ovarian cancer

Effective drug-antibody targeting using a novel monoclonal antibody against the proliferative compartment of mammalian squamous carcinomas

MAb 170H.82: an evaluation of a novel panadenocarcinoma monoclonal antibody labelled with 99Tcm and with 111In

Decreased levels of circulating lytic anti-T in the serum of patients with metastatic gastrointestinal cancer: a correlation with disease burden

The effects of circulating antigen on the pharmacokinetics and radioimmunoscintigraphic properties of 99m Tc labelled monoclonal antibodies in cancer patients

Radioimmunoscintigraphy in patients with breast adenocarcinoma using technetium-99m labelled monoclonal antibody 170H.82: report of a phase II study

Suchergebnisse filtern